Corona Remedies Reports 21.9% Q1 Revenue Growth as EBITDA Margins Hit 22%
Corona Remedies reported a strong start to FY27, significantly outperforming the Indian Pharmaceutical Market across core therapy areas. The company achieved a net profit of ₹60.11 crore while successfully commercializing its advanced Europe-GMP approved hormonal manufacturing facility to drive future international expansion.
Zydus Lifesciences Launches REVAHALE, India's First Once-Daily Nebulised LAMA for COPD
Zydus Lifesciences has introduced REVAHALE, the first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) in India for COPD maintenance. This launch addresses a critical gap for patients who struggle with handheld inhalers, offering sustained 24-hour bronchodilation.
Alembic Pharmaceuticals Q1 Revenue Jumps 26% as US Generics Surge 49% YoY
Alembic Pharmaceuticals delivered a strong Q1 FY27 performance with consolidated revenue reaching INR 2,150 Cr. The growth was spearheaded by a 49% surge in the US Generics business and a 33% increase in the API segment, leading management to raise the overall annual growth guidance.
Kwality Pharmaceuticals Q1FY27: Revenue Surges 45% as FY27 Guidance Raised to ₹700 Cr+
Kwality Pharmaceuticals Ltd reported a strong start to FY27 with revenue growing 45.7% year-on-year to ₹162.4 Cr. Following robust execution in regulated markets, management has upwardly revised its FY27 revenue guidance to over ₹700 Cr, citing increased visibility and a stronger product mix.
Gland Pharma Secures Strategic CDMO Order Worth ₹902.5 Crore from Global Pharma Major
Gland Pharma has entered into a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical firm for a portfolio of sterile injectable products. This collaboration covers 55 SKUs across three manufacturing sites and is expected to generate approximately ₹902.5 crore in annualized revenue starting from 2029.
Amrutanjan Health Care Starts ₹150 Cr Sanitary Napkin Plant in Telangana
Amrutanjan Health Care Limited has successfully commissioned its new ₹150 crore greenfield manufacturing facility in Telangana, marking a major capacity expansion for its feminine hygiene segment. The plant, equipped with high-speed Japanese technology, is designed to produce 700 million sanitary napkins annually to support the growth of its Comfy brand.
Lupin Launches Sugammadex Injection in US Following FDA Approval for Bridion Generic
Lupin Limited has announced the commercial launch of Sugammadex Injection in the United States following approval from the U.S. FDA. The product, a generic version of Merck's Bridion®, serves as a critical agent for reversing neuromuscular blockade in surgical patients.
Sakar Healthcare Q1 Results: Net Profit Surges 120% as Oncology Pivot Gains Momentum
Sakar Healthcare delivered a robust performance in Q1 FY27, marked by a 120% jump in net profit and a significant expansion of its specialized oncology segment. The company is successfully transitioning toward a vertically integrated, export-led oncology model with improving operational margins.
Gland Pharma Launches USFDA Approved Sugammadex Injection in 1.6 Billion Dollar US Market
Gland Pharma Limited has secured USFDA approval and executed the market launch of Sugammadex Injection in the United States. This generic alternative to Bridion targets a substantial perioperative therapy segment that recorded $1.6 billion in annual sales through April 2026.